Taiwan develops microfluidic platform for rapid screening of diseases
Taiwan develops microfluidic platform for rapid screening of diseases Taiwan develops microfluidic platform for rapid screening of diseases 18 January 2021 | News Personalized Antibiotic Screening Platform fAST automates both genotype and phenotype detections to identify bacteria within 1.5 hours and finish the multiple antibiotics combination test within 5 hours Photo Credit: PRNewswire Taiwan's Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the hea...
Source: biospectrumasia.com